Please login to the form below

Not currently logged in
Email:
Password:

melanoma

This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

The  U-turn means Opdivo is now approved as an adjuvant treatment for those with completely resected melanoma with lymph node involvement or metastatic disease. ... The drug was first given NICE approval for patients with advanced melanoma in 2016, but

Latest news

More from news
Approximately 77 fully matching, plus 251 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma

  • Packer Forbes appoints Jade McCudden Packer Forbes appoints Jade McCudden

    McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.

  • Array appoints Victor Sandor chief medical officer Array appoints Victor Sandor chief medical officer

    This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics